This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Dermatologic Disorders, Other  • Dermatology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Naila Usmani, MBChB, MRCP; Mark Goodfield, MBChB, MD

Arch Dermatol. 2007;143(7):873-877.

Background  Discoid lupus erythematosus is a chronic inflammatory condition in which the pathogenesis and the role of cell-mediated immunity remains unclear. Currently, the most effective treatments for severe disease are thalidomide, methotrexate, and cyclosporin, although the evidence for this is limited. Efalizumab is a monoclonal antibody directed against CD11a, the -subunit of the leukocyte-functioning antigen 1, with a current license for use in psoriasis. Because discoid lupus erythematosus is known to be predominantly T-cell mediated, our aim was to use efalizumab as a T-cell modulator in patients with recalcitrant disease.

Observations  Thirteen patients received efalizumab, with treatment responses varying from good to excellent in 12 of 13 patients. There was a significant reduction in the cutaneous lupus activity and severity score (CLASS) score after therapy with efalizumab (P = .002).

Conclusions  We have presented efalizumab as a novel alternative treatment for patients with difficult discoid lupus erythematosus. The response to treatment in 12 patients was very encouraging, with the mean time to response being 5.5 weeks. However, patient numbers were small, and many remain in the early stages of therapy. A prospective randomized study with a long-term follow-up is required, especially in light of recent findings to evaluate both the effectiveness and safety profile of this monoclonal antibody.

Author Affiliations: Department of Dermatology, Leeds General Infirmary, Leeds, England.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Response of Keratosis Lichenoides Chronica to Efalizumab Therapy
Munoz-Santos et al.
Arch Dermatol 2009;145:867-869.
FULL TEXT  

Early Diagnosis and Treatment of Discoid Lupus Erythematosus
Panjwani
J Am Board Fam Med 2009;22:206-213.
ABSTRACT | FULL TEXT  

Clinically Relevant Information About Cutaneous Lupus Erythematosus
Callen
Arch Dermatol 2009;145:316-319.
FULL TEXT  

Biologics Are Not Just for Psoriasis Anymore
Journal Watch Dermatology 2007;2007:1-1.
FULL TEXT